Non-small Cell Lung Cancer (PD-L1 Expression): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 72-year-old Caucasian male, who is a former smoker with a history of hypertension, diabetes, and BPH. He has NSCLC adenocarcinoma histology and is positive for the KRAS mutation G12C.

Originally posted on a forum in the ASCO Connection, participants now have the opportunity to claim CME, completion, or participation certificates for completing this activity. 

Learning Objectives

  • Evaluate the data for immune checkpoint inhibitors as second line therapy in patients with advanced NSCLC
  • Discuss the differences in efficacy based on PD-L1 status and smoking history 
  • Analyze the different antibodies and cut points being explored and how this applies to current practice 

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on April 27, 2019. Participants must complete all necessary course components by this date to receive credit.